

# Erratum to: Drug-Induced Phospholipidosis: Prediction, Detection, and Mitigation Strategies

Umesh M. Hanumegowda and Alicia Regueiro-Ren

Erratum to: Top Med Chem  
DOI: 10.1007/7355\_2013\_34

On page 281, references [36] and [37] had incorrect information. The correct information is given below:

36. Ishichi Y, Kimura E, Honda E, Yoshikawa M, Nakahata T, Terao Y, Suzuki A, Kawai T, Arakawa Y, Ohta H, Kanzaki N, Nakagawa H, Terauchi J (2013) Novel triple reuptake inhibitors with low risk of CAD associated liabilities: design, synthesis and biological activities of 4-[(1*S*)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds. *Bioorg Med Chem* 21:4600–4613
37. Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Furuta Y, Sakai M, Horiguchi M, Masui Y, Okazaki K, Sato Y, Nakahira H (2012) Discovery of 3*H*-imidazo [4,5-*c*]quinolin-4(5*H*)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. *Bioorg Med Chem* 20:5864–5883

---

The online version of the original chapter can be found under  
DOI: 10.1007/7355\_2013\_34

---

---

U.M. Hanumegowda  
Discovery Toxicology, Bristol-Myers Squibb Research and Development, Wallingford,  
CT 06492, USA

A. Regueiro-Ren (✉)  
Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford,  
CT 06492, USA  
e-mail: [Alicia.regueiroren@bms.com](mailto:Alicia.regueiroren@bms.com)